1067230-65-2

Basic information

• Product Name: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(R)-3-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(R)-N-BOC-3-BROMOMETHYLPYRROLIDINE;(3R)-3-(Bromomethyl)-1-pyrrolidinecarboxylic acid tert-butyl ester;(R)-Tert-butyl 3-(bromomethyl)pyrrolidine-1-carboxylate;(R)-1-Boc-3-(broMoMethyl)pyrrolidine;tert-butyl (3R)-3-(broMoMethyl)pyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 3-(bromomethyl)-, 1,1-dimethylethyl ester, (3R)-
• CAS NO: 1067230-65-2
• Molecular Formula: C₁₀H₁₈BrNO₂
• Molecular Weight: 264.16
• Mol File: 1067230-65-2.mol

Chemical Properties

• Boiling Point: 300.1±15.0 °C(Predicted)
• Appearance: /
• Density: 1.312
• Storage Temp.: 2-8°C
• PKA: -2.14±0.40(Predicted)
• CAS DataBase Reference: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(1067230-65-2)
• EPA Substance Registry System: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(1067230-65-2)

Safety Data

• Hazardous Substances Data: 1067230-65-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate for the synthesis of pharmaceuticals, specifically in the production of antiviral and antifungal agents. Its role in the development of these medications is crucial due to its ability to contribute to the creation of effective treatments against viral and fungal infections.
Used in Research and Development:
In the field of research and development, 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is employed as a building block in the synthesis of new drug therapies. Its potential for further research and application in the pharmaceutical and chemical industries is significant, as it aids in the discovery and production of innovative pharmaceutical compounds.
Used in Organic Synthesis:
3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is also utilized in organic synthesis, where it serves as a valuable component in the creation of complex organic molecules. Its versatility in this field allows for the development of a wide range of chemical products and contributes to the advancement of organic chemistry.

Upstream product

• 138108-72-2 tert-butyl (R)-3-hydroxymethylpyrrolidine-1-carboxylate 
• 177947-76-1 (3R)-1-(tert-butoxycarbonyl)-3-[(methane-sulfonyloxy)methyl]pyrrolidine 

Downstream Products

• 1433607-45-4 (3R)-N-Boc-3-(((((E)-2-amino-7-(4-fluoro-2-(pyridin-3-yl)phenyl)-4-methyl-7,8-dihydro-6H-quinazolin-5ylidene)amino)oxy)methyl)pyrrolidine 
• 1579514-47-8 (S)-methyl 2-(4-bromophenyl)-3-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate 
• 1579511-80-0 (S)-tert-butyl 3-((2-(4-bromophenyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC

Described as a Btk inhibitor, ibrutinib also potently inhibits Bmx and EGFR, two good targets for lung cancer. Owing to its high CLogP (4.07) and low aqueous solubility (a potent anti-cancer agent B6, with beneficial physicochemical parameters (CLogP = 2.56, solubility in water ≈ 0.1 mg/ml) meeting the principles of oral drugs. B6 exhibited anti-proliferation activities against EGFR-expressing cells, especially the mutant ones, such as H1975 (L858R/T790M, IC50 = 0.92 ± 0.19 μM) and HCC827 (Del119 IC50 = 0.014 ± 0.01 μM). Moreover, B6 significantly slowed down H1975 tumor growth with anti-tumor rate of 73.9% (p 50 = 35.7 ± 0.1 nM) over other kinases. So, as a potent Bmx inhibitor, B6 has the potential to be an efficacious treatment for NSCLC with acquired drug resistance.

QUINAZOLINE DERIVATIVES WITH HSP90 INHIBITORY ACTIVITY

Compounds of general formula (I): or a stereoisomer, tautomer, polymorph, hydrate, solvate, or a pharmaceutically acceptable salt thereof, wherein R is as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as proliferative diseases, e.g. cancers, viral and fungal infections, neurodegenerative or inflammatory diseases or conditions. The invention also relates to the preparation of these compounds as well as to pharmaceutical compositions comprising them.